Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Kobenahvn O, Denmark Clinical Trials

A listing of Kobenahvn O, Denmark clinical trials actively recruiting patients volunteers.

RESULTS

Found (20) clinical trials

Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure

Patients with the most severe type of sepsis, those with septic shock have a mortality rate between 30% to 45% due to multiple organ failure. The poor outcome of shocked patients, and especially those with sepsis, may by related to microvascular endothelial dysfunction. Evidence support that iloprost infusion significantly improved ...

Phase

0.0 miles

Learn More »

Culprit Lesions in NSTEMI With Multi Vessel Disease (NSTEMI-CULPRIT)

Background Acute myocardial infarction owes to a plaque rupture resulting in total (STEMI) or partial occlusion (NSTEMI) of the coronary artery. Current guidelines in NSTEMI recommend an invasive coronary angiogram (CAG) and possible treatment with percutaneous intervention (PCI) within 2-72 hours. In NSTEMI patients and multi vessel disease (MVD), identification ...

Phase N/A

0.0 miles

Learn More »

Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI

In patients with acute myocardial infraction (AMI) only 25-33% have entirely normal left ventricular (LV) systolic and diastolic function. Studies have show that echocardiographic signs of increased LV filling pressure (diastolic dysfunction) are associated with poor outcome after AMI. The optimal management of this group of patients is currently not ...

Phase

0.0 miles

Learn More »

Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease

Aim: To investigate whether a Family Caregiver Support Model intervention (FAM-CARE) is feasible and safe, and the impact on the caregiving role and psychosocial wellbeing in family caregivers of newly diagnosed patients with hematological malignancies, and former caregivers (family caregiver ambassadors). Design and Methods: This study is a one arm ...

Phase N/A

0.0 miles

Learn More »

The SIMBA Project - The Effect of a Prebiotic Supplement on Glucose Metabolism and Gut Microbiota in Obese Adults

The overall objective of this study is to investigate a fermented canola-seaweed (FCS) product in obese human subjects with increased risk of metabolic syndrome (MS). We will study the effects of the FCS on glucose handling and related cardiometabolic traits such as dyslipidemia and low-grade systemic inflammation. Finally, we will ...

Phase N/A

2.14 miles

Learn More »

The Effect of High vs. Moderate Protein Consumption on Human Health

The study will be conducted as a parallel randomized controlled intervention trial, initiated by eight weeks rapid weight loss with one of two VLCDs, one week of reintroducing regular foods, and 12 weeks with one of two different ad libitum diets; in total 21 weeks. The study will be blinded ...

Phase N/A

2.14 miles

Learn More »

An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis

The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study. The study provides for 7 years of additional treatment with baricitinib.

Phase

2.14 miles

Learn More »

ATOR-1015 First-in-human Study

The aim of the study is to investigate the safety and tolerability of ATOR-1015 when administered as repeated intravenous infusions to patients with advanced and/or refractory solid malignancies.

Phase

2.25 miles

Learn More »

Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer

A randomized multi-arm study evaluating the safety and efficacy of nivolumab versus placebo in combination with paclitaxel in participants with ER+/HER2- breast cancer

Phase

2.34 miles

Learn More »

Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)

This study is a post-market clinical follow-up (PMCF) study to identify and evaluate residual risks associated with the use of the BIOMONITOR III that are discovered or remain even after risk analysis, risk mitigation and successful conformity assessment. Furthermore, this study will also provide additional data as required by regulatory ...

Phase N/A

3.08 miles

Learn More »